Aspire Biopharma Holdings (ASBP) Revenue (2025 - 2026)

Aspire Biopharma Holdings (ASBP) posted quarterly Revenue of $28353.0 for Q1 2026, up 565.41% quarter-over-quarter from $4261.0 in Q4 2025.

Aspire Biopharma Holdings (ASBP) Revenue (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has reported Revenue for 2 consecutive years, with $28353.0 the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.61 Bn	131.75 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	65.28 Bn	60.09 Bn	1.37 Bn	1.52 Bn
4	Moderna	59.14 Bn	54.00 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	42.13 Bn	37.03 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.83 Bn	28.52 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.07 Bn	9.68 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.54 Bn	26.38 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	674.14 Mn
10	Aspire Biopharma Holdings	8.35 Mn	-3.82 Mn	-30,086.00	63,104.00

Download Data